Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND 2: Durable-Response Therapy Evaluation For Type 1 Diabetes Mellitus
2010-018775-17Phase 3Completed
- Sponsor
- GSK
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Otelixizumab 8‑day infusion with Placebo (2 arms). Primary endpoint: Change from baseline in 2‑hour mixed meal‑stimulated C‑peptide AUC at Month 12. Started May 2010; status: completed.
02
Drugs
otelixizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2010-018775-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018775-17.